このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

治療にイベルドマイドを追加する試験:再発、治療に反応しない、または悪化した神経芽腫患者を対象に

2026年11月5日 更新者:National Cancer Institute (NCI)

以前の化学免疫療法後の再発、難治性、または進行性神経芽腫を有する小児患者におけるイベルドミド併用または非併用のジヌツキシマブ/シクロホスファミド/トポテカン/サルグラモスチム(GM-CSF)の第1/2相試験

This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy drugs and to see how well it works in treating patients with neuroblastoma that has come back after a period of improvement (relapsed), that does not respond to treatment (refractory), or that is growing, spreading, or getting worse (progressive) following prior chemoimmunotherapy. Iberdomide is a cereblon-modulating agent. It works by helping the immune system kill tumor cells. Chemoimmunotherapy is chemotherapy combined with immunotherapy. Chemotherapy drugs, such as cyclophosphamide and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with dinutuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Granulocyte-macrophage colony-stimulating factors (GM-CSF), such as sargramostim, may increase the production of blood cells and may help the immune system recover from the side effects of chemotherapy. Giving iberdomide with chemoimmunotherapy may be safe, tolerable, and/or effective in treating patients with relapsed, refractory, or progressive neuroblastoma following prior chemoimmunotherapy.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

PRIMARY OBJECTIVES:

I. To identify a recommended phase 2 dose (RP2D) of iberdomide administered in combination with dinutuximab, cyclophosphamide, topotecan, and GM-CSF in patients with relapsed, refractory, or progressive neuroblastoma previously treated with chemoimmunotherapy. (Phase 1 dose escalation) II. To evaluate whether the addition of iberdomide to dinutuximab, cyclophosphamide, topotecan, and GM-CSF is associated with an improved response rate compared to dinutuximab, cyclophosphamide, topotecan, and GM-CSF in patients with refractory, relapsed, or progressive neuroblastoma previously treated with chemoimmunotherapy. (Phase 2 efficacy)

SECONDARY OBJECTIVES:

I. To evaluate the preliminary response rate of the addition of iberdomide to dinutuximab, cyclophosphamide, topotecan, and GM-CSF in patients with refractory, relapsed, or progressive neuroblastoma previously treated with chemoimmunotherapy. (Phase 1 dose escalation) II. To compare progression-free survival (PFS), overall survival (OS), confirmed response rate, and duration of response (DOR) between patients receiving dinutuximab, cyclophosphamide, topotecan, and GM-CSF with and without the addition of iberdomide.

III. To describe the toxicity profile of the combination of dinutuximab, cyclophosphamide, topotecan, and GM-CSF with and without iberdomide.

EXPLORATORY OBJECTIVES:

I. To characterize the pharmacokinetics and pharmacodynamics of iberdomide in combination with dinutuximab, cyclophosphamide, topotecan, and GM-CSF.

II. To characterize the circulating immune profile of patients treated with and without the addition of iberdomide to the dinutuximab, cyclophosphamide, topotecan, and GM-CSF backbone and explore associations with response to therapy.

III. To evaluate associations between GD2 levels in tumor cells from patient bone marrow samples and response to therapy.

IV. To collect and bank peripheral blood and tumor tissue (archival and fresh tissue from primary tumor resection or relapse, if available) for future biomarker studies.

OUTLINE: This is a phase I, dose-escalation study of iberdomide in combination with cyclophosphamide (CPM), topotecan (Topo), dinutuximab (DIN) and sargramostim (GM-CSF) followed by a phase II study. Patients are assigned to 1 of 2 phases.

PHASE 1: Patients receive iberdomide orally (PO), via nasogastric (NG)-tube, or via gastric (G)-tube once daily (QD) on days 1-14 or 1-21, cyclophosphamide intravenously (IV) over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim subcutaneously (SC) or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until absolute neutrophil count (ANC) is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

PHASE 2: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive iberdomide PO, via NG-tube, or via G-tube QD on days 1-14 or 1-21, as determined in phase 1, cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Additionally, all patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and biopsy, computed tomography (CT) or magnetic resonance imaging (MRI), and iobenguane I-123 (123I-MIBG) scans or fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) throughout the study. All patients also undergo blood sample collection on study.

After completion of study treatment, patients are followed up at 30 days, 3, 6, and 12 months, every 6 months for years 2-3, and then yearly for years 4-5.

研究の種類

介入

入学 (推定)

76

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Oakland、California、アメリカ、94607
        • 募集
        • Children's Oncology Group
        • 主任研究者:
          • Kieuhoa T. Vo
        • コンタクト:
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • 募集
        • Lurie Children's Hospital-Chicago
        • コンタクト:
          • Site Public Contact
          • 電話番号:773-880-4562
        • 主任研究者:
          • Elizabeth A. Sokol
    • New York
      • New York、New York、アメリカ、10065
        • 募集
        • Memorial Sloan Kettering Cancer Center
        • コンタクト:
          • Site Public Contact
          • 電話番号:212-639-7592
        • 主任研究者:
          • Fiorella Iglesias
    • South Carolina
      • Columbia、South Carolina、アメリカ、29203
        • 募集
        • Prisma Health Richland Hospital
        • 主任研究者:
          • Stuart L. Cramer
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1年~30年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients must be ≥ 1 year of age and ≤ 30 years of age at the time of study enrollment

  • Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines (i.e. > 2 x upper limit of normal [ULN]), at the time of initial diagnosis

  • Progressive/relapsed or refractory (defined as persistent disease with overall response no better than minor response [MR] to prior therapy per revised International Neuroblastoma Response Criteria [INRC]) neuroblastoma based on the revised INRC

  • Patients must meet ONE of the following criteria:

    • Primary refractory disease

      • Primary refractory disease following chemoimmunotherapy as part of induction therapy (e.g., ANBL17P1, ANBL2131 Arm B). Patients with primary refractory disease must have received at least 4 cycles of frontline high-risk induction chemoimmunotherapy

      • Primary refractory disease following aggressive multi-drug induction chemotherapy on or according to a high-risk NB protocol (e.g., A3973, ANBL0532, ANBL09P1, ANBL12P1, ANBL1531, or ANBL2131 Arm A) with persistent disease at the conclusion of at least 4 cycles of chemoimmunotherapy used as extended induction or pre-consolidation intensification of therapy for primary refractory disease (e.g., ANBL2131 Arm A with extended induction, ANBL1221, or ANBL1821)

        • NOTE: Patients who experienced disease progression either during or within 30 days of completion (last day of anti-GD2 antibody) of chemoimmunotherapy during induction or extended induction are not eligible for the study
    • Relapsed/progressive disease

      • First episode of recurrence following chemoimmunotherapy as part of induction therapy (e.g., ANBL17P1, ANBL2131 Arm B) or extended induction (e.g., ANBL2131 Arm A)

        • NOTE: Patients who experienced disease progression either during or within 30 days of completion (last day of anti-GD2 antibody) of chemoimmunotherapy during induction or extended induction are not eligible for the study
      • First episode of recurrent/progressive disease detected during or following chemoimmunotherapy used as part of post-consolidation therapy (e.g., ANBL19P1)

      • Second episode of recurrent/progressive disease detected during or following chemoimmunotherapy used as first-line salvage therapy for recurrent or progressive disease (e.g., ANBL1221, ANBL1821). Patients with stable disease after receiving chemoimmunotherapy for first relapse are not eligible (must be primary refractory disease)

  • Evaluable or measurable disease per the revised INRC

    • Measurable soft tissue disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 that is metaiodobenzylguanidine (MIBG) avid or demonstrates increased FDG uptake on PET scan

    • Evaluable disease is defined as either:

      • MIBG-avid lesions only (detected on MIBG scan with positive uptake at minimum of one site that do not meet criteria for measurable disease. This site(s) must represent disease recurrence after completion of therapy, progressive disease on therapy, or refractory disease during induction). OR
      • New bone site that is avid for FDG-PET (MIBG non-avid tumors) AND has CT/MRI findings consistent with tumor OR has been confirmed by biopsy
    • Patients with resistant/refractory soft tissue disease that is not MIBG avid or does not demonstrate increased FDG uptake on PET scan must undergo biopsy to document the presence of viable neuroblastoma to be considered a site of disease. Biopsy is not required for patients who have a new site of soft tissue disease or radiographic evidence of disease progression regardless of whether progression occurs while receiving therapy or after completion of therapy

      • NOTE: Patients with bone marrow only disease are not eligible. Patients with only elevated catecholamines (i.e. > 2 x ULN) are also not eligible for this study
  • Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients ≤ 16 years of age

  • For the purposes of this study, "chemoimmunotherapy" is defined as a regimen utilizing any anti-GD2 antibody in combination with cytotoxic chemotherapy, with doses of chemotherapy similar to those used in ANBL1221, ANBL1821, ANBL17P1, ANBL2131, and ANBL19P1

  • Patient must have received one and NO MORE THAN one prior chemoimmunotherapy-containing regimen

    • NOTE: Patients who received ANBL2131 Arm B therapy or a similar regimen including anti-GD2 antibody in combination with chemotherapy and then received an extended induction with chemoimmunotherapy (regardless of whether the chemoimmunotherapy was administered for relapse, progression, or poor end of induction response) will be considered to have received two regimens of chemoimmunotherapy. Similarly, patients who receive chemoimmunotherapy during induction or extended induction and then receive chemoimmunotherapy in post-consolidation (e.g., per ANBL19P1) will be considered to have received two regimens of chemoimmunotherapy. These patients are not eligible for this trial
  • Patient cannot have received more than two prior lines of therapy, including frontline therapy

    • Standard high-risk induction with or without extended induction followed by consolidation and post-consolidation immunotherapy with or without eflornithine (DFMO) continuation therapy will be considered one line of therapy

    • ANBL2131 Arm B induction without extended induction followed by consolidation and post-consolidation immunotherapy with or without DFMO continuation therapy will be considered one line of therapy

      • NOTE: Induction on ANBL2131 Arm B extended induction, and post-consolidation chemoimmunotherapy are each considered separate regimens for the purposes of counting the number of chemoimmunotherapy regimens. In addition, patients who received ANBL2131 Arm B therapy or a similar regimen including anti-GD2 antibody in combination with chemotherapy who received another line of relapse therapy following Arm B or similar treatment are also not eligible
    • In the relapse setting, one line of therapy will be considered at least one delivered cycle of chemoimmunotherapy (with no limit on the number of consecutive cycles of chemoimmunotherapy)

      • NOTE: A change in the chemotherapy regimen or anti-GD2 antibody will be considered an additional line of chemoimmunotherapy and these patients will not be eligible for the trial
    • In the refractory setting where chemoimmunotherapy was used as extended induction or pre-consolidation intensification of therapy for primary refractory disease, one line of therapy will be considered at least 4 delivered cycles of chemoimmunotherapy (with no limit on the number of consecutive cycles of chemoimmunotherapy)

      • NOTE: A change in the chemotherapy regimen or anti-GD2 antibody will be considered an additional line of chemoimmunotherapy and these patients will not be eligible for the trial
  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study

  • Myelosuppressive chemotherapy: Must not have received within 14 days (2 weeks) of entry onto this study

  • Biologic (anti-neoplastic agent): Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or ANC counts): ≥ 7 days after the last dose of agent. See Developmental Therapeutics Committee (DVL) homepage for commercial and Phase 1 investigational agent classifications

  • Antibodies: ≥ 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade ≤ 1

  • Radiation therapy (RT):

    • ≥ 7 days must have elapsed from small port radiation; ≥ 12 weeks must have elapsed from large field radiation therapy (i.e., total body irradiation, craniospinal, whole abdominal, total lung, > 50% marrow space); ≥ 6 weeks from other substantial bone marrow radiation
    • Lesions that have been previously radiated cannot be used as target lesions unless there is radiographic evidence of progression at the site following radiation or a biopsy done following radiation shows viable neuroblastoma. Palliative radiation while on study is not permitted
  • Stem cell transplant (SCT): Patients are eligible ≥ 6 weeks after autologous stem cell transplants or stem cell infusions (including stem cell infusions given as supportive care following iobenguane I-131 [131I-MIBG] therapy) as long as hematologic and other eligibility criteria have been met

  • 131I-MIBG therapy: Patients who previously received 131I-MIBG therapy for relapsed/refractory disease or poor end of induction response are not eligible

    • Prior receipt of 131I-MIBG therapy as part of planned frontline Induction therapy (e.g., ANBL09P1, ANBL1531) is allowed. Patients are eligible ≥ 6 weeks after therapeutic 131I-MIBG provided that all other eligibility criteria are met
  • Growth factor: Patients must not have received long-acting myeloid growth factors (e.g. pegfilgrastim) within 14 days of entry on this study. Seven days must have elapsed since administration of a short-acting myeloid growth factor or platelet growth factor/stimulating agents (e.g., romiplostim, eltrombopag)

  • Intravenous immunoglobulin (IVIG): Patients must not have received IVIG within 14 days of study entry

  • Known HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • Peripheral absolute neutrophil count (ANC) ≥ 1000/uL (performed within 7 days prior to enrollment)

    • Patients known to have bone marrow involvement with neuroblastoma are eligible provided that the minimum ANC and transfusion independent platelet count criteria are met
  • Platelet count ≥ 100,000/uL (transfusion independent) (performed within 7 days prior to enrollment)

    • Patients known to have bone marrow involvement with neuroblastoma are eligible provided that the minimum ANC and transfusion independent platelet count criteria are met
  • A serum creatinine based on age/sex as follows: (performed within 7 days prior to enrollment)

    • Age: 1 to < 2 years; Maximum serum creatinine (mg/dL): 0.6 (male) 0.6 (female)
    • Age: 2 to < 6 years; Maximum serum creatinine (mg/dL): 0.8 (male) 0.8 (female)
    • Age: 6 to < 10 years; Maximum serum creatinine (mg/dL): 1 (male) 1 (female)
    • Age: 10 to < 13 years; Maximum serum creatinine (mg/dL): 1.2 (male) 1.2 (female)
    • Age: 13 to < 16 years; Maximum serum creatinine (mg/dL): 1.5 (male) 1.4 (female)
    • Age: ≥ 16 years; Maximum serum creatinine (mg/dL): 1.7 (male) 1.4 (female) OR - a 24-hour urine creatinine clearance ≥ 60 mL/min/1.73 m^2 OR - a glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2. If used for eligibility, GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
    • Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age or ≤ 3.0 mg/dL for patients with documented Gilbert's syndrome (performed within 7 days prior to enrollment)

  • Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) ≤ 135 U/L (performed within 7 days prior to enrollment)

    • Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
  • Shortening fraction of ≥ 27% by echocardiogram (ECHO), OR ejection fraction of ≥ 50% by ECHO or grated radionuclide study (obtained within 21 days prior to enrollment and start of protocol therapy)

  • No evidence of dyspnea at rest, no exercise intolerance, no chronic oxygen requirement, and room air pulse oximetry > 94% if there is a clinical indication for pulse oximetry. Normal pulmonary function tests in patients who are capable of cooperating with testing (including diffusion capacity of the lung for carbon monoxide [DLCO]) are required if there is a clinical indication for determination. For patients who do not have respiratory symptoms, full pulmonary function testing (PFTs) are NOT required (obtained within 21 days prior to enrollment and start of protocol therapy)

  • Patients with a history of central nervous system (CNS) metastatic disease must have no clinical or radiological evidence of active CNS disease at the time of study enrollment. Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled

  • CNS toxicity ≤ grade 2

Exclusion Criteria:

  • Patients who received allogeneic stem cell therapy will be excluded
  • Patients must have been off pharmacologic doses of systemic steroids for at least 7 days prior to enrollment. Patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study are ineligible. The only exception is for patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration in order to avoid allergic transfusion reactions. The use of conventional doses of inhaled steroids for the treatment of asthma is permitted, as is the use of physiologic doses of steroids for patients with known adrenal insufficiency. Patients on any other immunosuppressive medications (e.g. cyclosporine, tacrolimus) are not eligible
  • Patients with untreated CNS disease will be excluded. If the CNS disease has been adequately treated (e.g., surgical resection and radiation; or radiation alone) and there is no evidence of progression in the CNS, then the patient will be eligible
  • Patients with a history of having to permanently discontinue anti-GD2 therapy or sargramostim (GM-CSF) due to drug-related toxicity will be excluded
  • Patients with a history of grade 4 allergic reactions or other drug-related toxicities that required permanent discontinuation of dinutuximab, dinutuximab-beta, naxitamab-gqgk, or sargramostim (GM-CSF) will be excluded
  • Patients with myelodysplastic syndrome or with any other malignancy other than neuroblastoma will be excluded
  • Patients with prior exposure to iberdomide will be excluded
  • Patients with a history of serious allergic reaction to another immunomodulatory agent (e.g., thalidomide, lenalidomide, or pomalidomide) will be excluded
  • Patients who are unable to tolerate oral/nasogastric/gastrostomy medications will not be eligible for this trial. Additionally, patients with significant malabsorption such as chronic gastrointestinal diseases (e.g., inflammatory bowel disease) or significant bowel resection that would preclude adequate oral medication absorption will be excluded
  • Patients must not have received enzyme-inducing anticonvulsants including but not limited to phenytoin, phenobarbital, or carbamazepine for at least 7 days prior to study enrollment. Patients receiving non-enzyme inducing anticonvulsants such as gabapentin, valproic acid, or levetiracetam will be eligible
  • Patients who have received drugs that are strong inducers or inhibitors of CYP3A4 within 14 days prior to study enrollment are not eligible
  • Patients with history of prior unprovoked thrombosis/thromboembolic events are not eligible. Patients with a history of provoked thrombosis/thromboembolic events (e.g., related to central lines) are eligible if they no longer require anti-coagulation or have been on a stable dose of anticoagulation therapy for at least 6 weeks before the first dose of study treatment and have no complications from the thrombosis/thromboembolic event or the anticoagulation regimen
  • Patients who have an uncontrolled infection are not eligible
  • Patients with peripheral neuropathy ≥ grade 2 are excluded
  • Patients with a significant intercurrent illness (any ongoing serious medical problem unrelated to cancer or its treatment) that is not covered by the detailed exclusion criteria and that is expected to interfere with the action of study agents or to significantly increase the severity of the toxicities experienced from study treatment are not eligible
  • Patients who experienced disease progression either during or within 30 days of completion of chemoimmunotherapy during induction or extended induction are not eligible for the study
  • Female patients who are pregnant are not eligible since fetal toxicities and teratogenic effects have been noted for several of the study drugs. Pregnancy tests and monthly counseling are required for individuals of childbearing potential. Male patients must practice complete abstinence or agree to use a condom during sexual contact with individuals of childbearing potential (IOCBP) while participating in the study, during dose interruptions, and for at least 28 days following discontinuation from the study, even if he has undergone a successful vasectomy
  • Lactating females who plan to breastfeed their infants are not eligible
  • Sexually active patients of reproductive potential who have not agreed to use two effective methods of contraception simultaneously without interruption, for at least 7 days before starting study treatment, throughout the entire duration of study treatment, during dose interruptions, and for at least 28 days after the last dose of iberdomide are not eligible. The two methods of contraception must include one highly effective method and one additional effective method
  • All patients and/or their parents or legal guardians must sign a written informed consent
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Phase 1 (iberdomide, CPM, Topo, DIN, GM-CSF)

Patients receive iberdomide PO, via NG-tube, or via G-tube QD on days 1-14 or 1-21, cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO or MUGA, bone marrow aspiration and biopsy, CT or MRI, and 123I-MIBG scans or FDG-PET throughout the study. Patients also undergo blood sample collection on study.

Given IV

他の名前:
  • シトキサン
  • CTX
  • (-)-シクロホスファミド
  • 2H-1,3,2-オキサザホスホリン、2-[ビス(2-クロロエチル)アミノ]テトラヒドロ-、2-オキシド、一水和物
  • カルロキサン
  • シクロホスファミダ
  • シクロホスファミド
  • シクロキサール
  • クラフェン
  • CP一水和物
  • サイクロセル
  • シクロスブラスチン
  • シクロブラスチン
  • シクロホスファム
  • シクロホスファミド一水和物
  • シクロホスファミダム
  • シクロホスファン
  • シクロホスファナム
  • シクロスチン
  • サイトホスファン
  • シトホスファン
  • フォスファセロン
  • ジェノクサル
  • ジェヌサル
  • レドキシン
  • ミトキサン
  • ネオサー
  • レビミューン
  • WR-138719
  • アスタB518
  • B-518
  • B518
  • WR 138719
  • WR138719
  • フリンドビックス

Undergo bone marrow biopsy

他の名前:
  • 骨髄の生検
  • 生検、骨髄

Undergo CT

他の名前:
  • CT
  • 猫
  • CATスキャン
  • コンピューター断層撮影
  • コンピュータ化されたアキシャルトモグラフィー
  • CTスキャン
  • トモグラフィー
  • コンピューター断層撮影 (手順)
  • コンピューター断層撮影 (CT) スキャン
  • 診断CATスキャン
  • 診断CATスキャンサービスタイプ

Undergo MRI

他の名前:
  • MRI
  • 磁気共鳴
  • 磁気共鳴画像スキャン
  • 医用画像、磁気共鳴 / 核磁気共鳴
  • 氏
  • MRイメージング
  • MRI スキャン
  • NMRイメージング
  • NMRI
  • 核磁気共鳴イメージング
  • 磁気共鳴画像法 (MRI)
  • sMRI
  • 磁気共鳴画像法(手順)
  • 構造MRI

Undergo ECHO

他の名前:
  • 心エコー検査
  • EC

Undergo MUGA

他の名前:
  • 血液プールスキャン
  • 平衡放射性核種血管造影
  • ゲーテッド血液プールイメージング
  • ムガ
  • 放射性核種心室造影
  • RNVG
  • SYMAスキャン
  • 同期マルチゲート取得スキャン
  • ムガスキャン
  • マルチゲート取得スキャン
  • 放射性核種脳室造影スキャン
  • ゲーテッドハートプールスキャン
  • RNVスキャン

Undergo bone marrow aspiration

Given IV

他の名前:
  • ヒカンプタミン
  • トポテカンラクトン

Undergo FDG-PET

他の名前:
  • FDG
  • FDG-PET
  • FDG-PETイメージング

Given IV

他の名前:
  • Ch14.18
  • カルジバ
  • Ch 14.18UTC
  • モアブ Ch14.18
  • モノクローナル抗体 Ch14.18
  • ユニツキシン
  • ジヌツキシマブ ベータ

Given PO, NG-tube, or G-tube

他の名前:
  • CC-220
  • CC220
  • Zenbexus

Undergo 123I-MIBG scans

他の名前:
  • 核医学画像診断

Given SC or IV

他の名前:
  • 23-L-ロイシンコロニー刺激因子 2
  • DRG-0012
  • ロイキン
  • プロカイン
  • rhu GM-CFS
  • サグラモスティム
  • サルグラモスタチン
アクティブコンパレータ:Phase 2 arm A (CPM, Topo, DIN, GM-CSF)

Patients receive cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO or MUGA, bone marrow aspiration and biopsy, CT or MRI, and 123I-MIBG scans or FDG-PET throughout the study. Patients also undergo blood sample collection on study.

Given IV

他の名前:
  • シトキサン
  • CTX
  • (-)-シクロホスファミド
  • 2H-1,3,2-オキサザホスホリン、2-[ビス(2-クロロエチル)アミノ]テトラヒドロ-、2-オキシド、一水和物
  • カルロキサン
  • シクロホスファミダ
  • シクロホスファミド
  • シクロキサール
  • クラフェン
  • CP一水和物
  • サイクロセル
  • シクロスブラスチン
  • シクロブラスチン
  • シクロホスファム
  • シクロホスファミド一水和物
  • シクロホスファミダム
  • シクロホスファン
  • シクロホスファナム
  • シクロスチン
  • サイトホスファン
  • シトホスファン
  • フォスファセロン
  • ジェノクサル
  • ジェヌサル
  • レドキシン
  • ミトキサン
  • ネオサー
  • レビミューン
  • WR-138719
  • アスタB518
  • B-518
  • B518
  • WR 138719
  • WR138719
  • フリンドビックス

Undergo bone marrow biopsy

他の名前:
  • 骨髄の生検
  • 生検、骨髄

Undergo CT

他の名前:
  • CT
  • 猫
  • CATスキャン
  • コンピューター断層撮影
  • コンピュータ化されたアキシャルトモグラフィー
  • CTスキャン
  • トモグラフィー
  • コンピューター断層撮影 (手順)
  • コンピューター断層撮影 (CT) スキャン
  • 診断CATスキャン
  • 診断CATスキャンサービスタイプ

Undergo MRI

他の名前:
  • MRI
  • 磁気共鳴
  • 磁気共鳴画像スキャン
  • 医用画像、磁気共鳴 / 核磁気共鳴
  • 氏
  • MRイメージング
  • MRI スキャン
  • NMRイメージング
  • NMRI
  • 核磁気共鳴イメージング
  • 磁気共鳴画像法 (MRI)
  • sMRI
  • 磁気共鳴画像法(手順)
  • 構造MRI

Undergo ECHO

他の名前:
  • 心エコー検査
  • EC

Undergo MUGA

他の名前:
  • 血液プールスキャン
  • 平衡放射性核種血管造影
  • ゲーテッド血液プールイメージング
  • ムガ
  • 放射性核種心室造影
  • RNVG
  • SYMAスキャン
  • 同期マルチゲート取得スキャン
  • ムガスキャン
  • マルチゲート取得スキャン
  • 放射性核種脳室造影スキャン
  • ゲーテッドハートプールスキャン
  • RNVスキャン

Undergo bone marrow aspiration

Given IV

他の名前:
  • ヒカンプタミン
  • トポテカンラクトン

Undergo FDG-PET

他の名前:
  • FDG
  • FDG-PET
  • FDG-PETイメージング

Given IV

他の名前:
  • Ch14.18
  • カルジバ
  • Ch 14.18UTC
  • モアブ Ch14.18
  • モノクローナル抗体 Ch14.18
  • ユニツキシン
  • ジヌツキシマブ ベータ

Undergo 123I-MIBG scans

他の名前:
  • 核医学画像診断

Given SC or IV

他の名前:
  • 23-L-ロイシンコロニー刺激因子 2
  • DRG-0012
  • ロイキン
  • プロカイン
  • rhu GM-CFS
  • サグラモスティム
  • サルグラモスタチン
実験的:Phase 2 arm B (iberdomide, CPM, Topo, DIN, GM-CSF)

Patients receive iberdomide PO, via NG-tube, or via G-tube QD on days 1-14 or 1-21, as determined in phase 1, cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO or MUGA, bone marrow aspiration and biopsy, CT or MRI, and 123I-MIBG scans or FDG-PET throughout the study. Patients also undergo blood sample collection on study.

Given IV

他の名前:
  • シトキサン
  • CTX
  • (-)-シクロホスファミド
  • 2H-1,3,2-オキサザホスホリン、2-[ビス(2-クロロエチル)アミノ]テトラヒドロ-、2-オキシド、一水和物
  • カルロキサン
  • シクロホスファミダ
  • シクロホスファミド
  • シクロキサール
  • クラフェン
  • CP一水和物
  • サイクロセル
  • シクロスブラスチン
  • シクロブラスチン
  • シクロホスファム
  • シクロホスファミド一水和物
  • シクロホスファミダム
  • シクロホスファン
  • シクロホスファナム
  • シクロスチン
  • サイトホスファン
  • シトホスファン
  • フォスファセロン
  • ジェノクサル
  • ジェヌサル
  • レドキシン
  • ミトキサン
  • ネオサー
  • レビミューン
  • WR-138719
  • アスタB518
  • B-518
  • B518
  • WR 138719
  • WR138719
  • フリンドビックス

Undergo bone marrow biopsy

他の名前:
  • 骨髄の生検
  • 生検、骨髄

Undergo CT

他の名前:
  • CT
  • 猫
  • CATスキャン
  • コンピューター断層撮影
  • コンピュータ化されたアキシャルトモグラフィー
  • CTスキャン
  • トモグラフィー
  • コンピューター断層撮影 (手順)
  • コンピューター断層撮影 (CT) スキャン
  • 診断CATスキャン
  • 診断CATスキャンサービスタイプ

Undergo MRI

他の名前:
  • MRI
  • 磁気共鳴
  • 磁気共鳴画像スキャン
  • 医用画像、磁気共鳴 / 核磁気共鳴
  • 氏
  • MRイメージング
  • MRI スキャン
  • NMRイメージング
  • NMRI
  • 核磁気共鳴イメージング
  • 磁気共鳴画像法 (MRI)
  • sMRI
  • 磁気共鳴画像法(手順)
  • 構造MRI

Undergo ECHO

他の名前:
  • 心エコー検査
  • EC

Undergo MUGA

他の名前:
  • 血液プールスキャン
  • 平衡放射性核種血管造影
  • ゲーテッド血液プールイメージング
  • ムガ
  • 放射性核種心室造影
  • RNVG
  • SYMAスキャン
  • 同期マルチゲート取得スキャン
  • ムガスキャン
  • マルチゲート取得スキャン
  • 放射性核種脳室造影スキャン
  • ゲーテッドハートプールスキャン
  • RNVスキャン

Undergo bone marrow aspiration

Given IV

他の名前:
  • ヒカンプタミン
  • トポテカンラクトン

Undergo FDG-PET

他の名前:
  • FDG
  • FDG-PET
  • FDG-PETイメージング

Given IV

他の名前:
  • Ch14.18
  • カルジバ
  • Ch 14.18UTC
  • モアブ Ch14.18
  • モノクローナル抗体 Ch14.18
  • ユニツキシン
  • ジヌツキシマブ ベータ

Given PO, NG-tube, or G-tube

他の名前:
  • CC-220
  • CC220
  • Zenbexus

Undergo 123I-MIBG scans

他の名前:
  • 核医学画像診断

Given SC or IV

他の名前:
  • 23-L-ロイシンコロニー刺激因子 2
  • DRG-0012
  • ロイキン
  • プロカイン
  • rhu GM-CFS
  • サグラモスティム
  • サルグラモスタチン

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Recommended phase 2 dose (Phase 1)
時間枠:Up to the completion of phase 1

Will be assessed by determining the recommended phase 2 dose of iberdomide administered in combination with dinutuximab, cyclophosphamide, topotecan, and granulocyte-macrophage colony-stimulating factor (GM-CSF) using the rolling six design.

Up to the completion of phase 1
Response rate (Phase 2)
時間枠:Post-randomization through the end of cycle 12 (Cycle length = 28 days)

Responders are defined as patients who achieve a minor response (MR) or better, per the revised International Neuroblastoma Response Criteria (INRC), as their best overall response at any time post-randomization through the end of cycle 12. The response rate by the end of 12 cycles as determined by central review will be calculated, including placement of a 95% confidence interval.

Post-randomization through the end of cycle 12 (Cycle length = 28 days)

二次結果の測定

結果測定
メジャーの説明
時間枠
Response rate (Phase 1)
時間枠:Up to 12 cycles (Cycle length = 28 days)

Responders are defined as patients who achieve a minor response (MR) or better, per the revised International Neuroblastoma Response Criteria (INRC), as their best overall response at any time through the end of cycle 12. The response rate by the end of 12 cycles as determined by the institution will be calculated, including placement of a 95% confidence interval.

Up to 12 cycles (Cycle length = 28 days)
Progression-free survival (Phase 2)
時間枠:Up to 1 year

Kaplan-Meier method will be used to estimate progression-free survival (PFS). PFS time will be calculated from the time of randomization to the occurrence of relapse, progressive disease, or death. Patients without a PFS event will be censored at the time of last follow-up. 1-Year PFS is provided.

Up to 1 year
Overall survival (Phase 2)
時間枠:Up to 1 year

Kaplan-Meier method will be used to estimate overall survival (OS). OS time will be calculated from the time of randomization to the occurrence of death. Patients still alive will be censored at the time of last follow-up.1-Year OS is provided.

Up to 1 year
Confirmed response rate (Phase 2)
時間枠:Up to 12 cycles (Cycle length = 28 days)

A confirmed response is defined as a minor response (MR) or better that is confirmed by a second disease evaluation obtained at least 4 weeks after first documentation of MR or better. The confirmed response rate will be provided.

Up to 12 cycles (Cycle length = 28 days)
Duration of response (Phase 2)
時間枠:Up to 5 years

Duration of response will be calculated as the time from first achievement of response to disease progression or death in patients who achieve a minor response (MR) or better. Duration of response will be provided.

Up to 5 years

その他の成果指標

結果測定
メジャーの説明
時間枠
Pharmacokinetic (PK) parameters of iberdomide in combination with dinutuximab, cyclophosphamide, topotecan, and GM-CSF
時間枠:Cycle (C) 1 day (D) 1, C1D2, and C1D8, 9, or 10 (Phase 1 patients) and C1D8, C2D8, and C3D8 (Phase 2 patients) (Cycle length = 28 days)

PK parameters of iberdomide in combination with dinutuximab, cyclophosphamide, topotecan, and GM-CSF at steady state will be performed. The PK parameters will be summarized with simple summary statistics, including means, medians, ranges and standard deviations.

Cycle (C) 1 day (D) 1, C1D2, and C1D8, 9, or 10 (Phase 1 patients) and C1D8, C2D8, and C3D8 (Phase 2 patients) (Cycle length = 28 days)
Pharmacodynamic (PD) parameters of iberdomide in combination with dinutuximab, cyclophosphamide, topotecan, and GM-CSF (Phase 1)
時間枠:C1D1 and C1D2 (Cycle length = 28 days)

PD parameters of iberdomide in combination with dinutuximab, cyclophosphamide, topotecan, and GM-CSF at steady state will be performed. The PD parameters will be summarized with simple summary statistics, including means, medians, ranges and standard deviations.

C1D1 and C1D2 (Cycle length = 28 days)
Immune profiling results (Phase 2)
時間枠:C1D1, C1D15 or 22, C2D1, C3D1, and at progression (Cycle length = 28 days)

Immune profiling results will be summarized with descriptive statistics, including describing changes in markers over time. Markers will be correlated with response via a chi-square test.

C1D1, C1D15 or 22, C2D1, C3D1, and at progression (Cycle length = 28 days)
GD2 levels in tumor cells from bone marrow samples and response
時間枠:After 6 cycles (Cycle length = 28 days)

Will correlate GD2 levels in tumor cells from bone marrow samples with response (responder versus non-responder) after 6 cycles using Fisher's exact test for categorical and the Wilcoxon rank-sum test for continuous factors.

After 6 cycles (Cycle length = 28 days)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Kieuhoa T Vo、Children's Oncology Group

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年6月25日

一次修了 (推定)

2029年9月30日

研究の完了 (推定)

2029年9月30日

試験登録日

最初に提出

2026年2月26日

QC基準を満たした最初の提出物

2026年2月26日

最初の投稿 (実際)

2026年2月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月6日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NCI-2026-01050
  • U10CA180886 (米国 NIH グラント/契約)
  • NCI-2026-01050 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
  • ANBL2421 (その他の識別子:CTEP)
  • ANBL2421 (その他の識別子:Children's Oncology Group)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。